

## NeonMind Lists on the Frankfurt Stock Exchange

Vancouver, British Columbia--(Newsfile Corp. - January 19, 2021) - **NeonMind Biosciences Inc. (CSE: NEON) (FSE: 6UF)** ("**NeonMind**"), a psychedelic drug development company, is pleased to announce its common shares are now trading on the Frankfurt Stock Exchange (the "**FSE**") under the symbol "**6FU**". As a result, NeonMind's common shares are now cross-listed on the Canadian Securities Exchange and the FSE.



NeonMind Lists on the Frankfurt Stock Exchange (FSE: 6UF)

To view an enhanced version of this image, please visit:

[https://orders.newsfilecorp.com/files/7646/72297\\_neonmindimage2.jpg](https://orders.newsfilecorp.com/files/7646/72297_neonmindimage2.jpg)

"Listing on the Frankfurt Stock Exchange will provide us an opportunity to grow our shareholder base throughout Europe and allow European investors to follow NeonMind's development in the psychedelic drug industry and be a part of our growth," said Penny White, Founder and CEO of NeonMind.

The Frankfurt Stock Exchange is one of the world's largest trading centres for securities. With a share in turnover of around 90 per cent, it is the largest of Germany's seven stock exchanges and it is an international trading centre, which is reflected in the structure of its participants. Of the approximately 200 market participants, roughly 50% are from countries other than Germany.

The FSE facilitates advanced electronic trading, settlement and information systems, allowing it to meet the growing requirements of cross-border trading.

### **About NeonMind Biosciences Inc.**

NeonMind is a preclinical drug development company. Its first proposed drug candidate involves the administration of psilocybin (a complex organic compound found in psychedelic mushrooms) as a treatment for obesity and related illnesses for which NeonMind is conducting a preclinical trial at the University of British Columbia. NeonMind has filed five U.S. provisional patent applications claiming methods of aiding in weight loss, treating compulsive eating disorder, treating obesity or a complication of obesity, and/or altering the diet of an individual by administering psilocybin and/or other psychedelic compounds or their analogues or by administering psilocybin or its analogue in conjunction with therapy or other treatments. NeonMind is also pursuing commercialization of its catalogue of proprietary medicinal mushroom product formulas. It recently launched a collection of four mushroom-infused coffees containing medicinal mushrooms Lion's Mane, Turkey Tail, Reishi and Cordyceps which are available for purchase online in Canada at [www.neonmind.com](http://www.neonmind.com).

For more information on NeonMind, go to [www.NeonMindbiosciences.com](http://www.NeonMindbiosciences.com) or buy NeonMind mushroom infused coffee at [www.NeonMind.com](http://www.NeonMind.com).

Penny White, President & CEO  
[penny@neonmind.com](mailto:penny@neonmind.com)  
1-866-318-6874

### **Investor Relations:**

Edge Communications  
[invest@neonmind.com](mailto:invest@neonmind.com)

### **Media Inquiries:**

Exvera Communications Inc.  
[brittany@exvera.com](mailto:brittany@exvera.com)

*The Canadian Securities Exchange has not reviewed, approved or disapproved the contents of this news release.*

### **Cautionary Statement Regarding Forward-Looking Statements**

*Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or NeonMind's future performance. The use of any of the words "could", "expect", "believe", "will", "projected", "estimated" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on NeonMind's current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, NeonMind's drug development plans, its ability to retain key personnel, and its expectation as to the development of its intellectual property and other steps in its preclinical and clinical drug development constitute forward-looking information. Actual results and developments may differ materially from those contemplated by forward-looking information. Readers are cautioned not to place undue reliance on forward-looking information. The statements made in this press release are made as of the date hereof. NeonMind disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as may be expressly required by applicable securities laws.*



To view the source version of this press release, please visit <https://www.newsfilecorp.com/release/72297>